Eyelash Lengthening Consultation
EZCare Clinic offers more than medical services. For those looking for a way to lengthen and volumize the lash line, come to our EZCare Clinic for a consultation on eyelash lengthening.
Eyelashes have a tendency to thin out over time, this is known as hypotrichosis. Years of rubbing, tugging, and poor makeup habits can all lead to eyelash breakage and fallout. Alopecia or those with a hyperthyroid issue can also experience eyelash thinning.
Our practitioners can provide an assessment, and if pertinent, can prescribe LATISSE®. LATISSE® is an at-home treatment that can give users longer, darker, and thicker lashes within 16 weeks of use. LATISSE® is an FDA-approved treatment that is applied once a night for gradual results. The active ingredient, bimatoprost, is believed to increase the length of the growth phase of eyelashes as well as increase the number of hairs that are produced during this phase.
At EZCare Clinic, our practitioners provide this service to patients 18 years or older, and insurance is not accepted for this service.
Patients with the following are not eligible for this service:
- Currently taking medicine to treat eye pressure including glaucoma
- Had eye surgery or Lasik® in the past year
- Have eye surgery or Lasik® planned in the next three months
- Have an active infection or recent injury to one or both eyes
- Have a lens implant or lens removed from one or both eyes
- Have eyelash loss as a result of chemotherapy
- This service is not available to pregnant women or women who are breastfeeding.
Important safety information about LATISSE®
If you use/used prescription products for eye pressure problems, use LATISSE® under doctor care. LATISSE® may cause increased brown pigmentation of the colored part of the eye which is likely permanent. Eyelid skin darkening may occur and may be reversible. Only apply at the base of upper lashes. DO NOT APPLY to lower lid. Hair may grow on skin that LATISSE® frequently touches. If you have eye problems/surgery, consult your doctor about the use of LATISSE®. Common side effects are itchy and red eyes. If discontinued, lashes gradually return to the previous appearance.
Indication: LATISSE® (bimatoprost ophthalmic solution) 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness, and darkness.
You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit MedWatch or call 1-800-FDA-1088.
Warnings and Precautions: In patients using LUMIGAN® (bimatoprost ophthalmic solution) or other prostaglandin analogs for the treatment of elevated intraocular pressure (IOP), the concomitant use of LATISSE® may interfere with the desired reduction in IOP. Patients using prostaglandin analogs including LUMIGAN® for IOP reduction should only use LATISSE® after consulting with their physician and should be monitored for changes to their intraocular pressure.
Increased iris pigmentation has occurred when bimatoprost solution was administered. Patients should be advised about the potential for increased brown iris pigmentation, which is likely to be permanent.
Bimatoprost has been reported to cause pigment changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is expected to increase as long as bimatoprost is administered, but has been reported to be reversible upon discontinuation of bimatoprost in most patients.
There is the potential for hair growth to occur in areas where LATISSE® solution comes in repeated contact with skin surfaces. Apply LATISSE® only to the skin of the upper eyelid margin at the base of the eyelashes.
LATISSE® solution should be used with caution in patients with active intraocular inflammation (eg, uveitis) because the inflammation may be exacerbated.
Macular edema, including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic solution (LUMIGAN®) for elevated IOP. LATISSE® should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
Adverse reactions: The most frequently reported adverse events were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye symptoms, and erythema of the eyelid. These events occurred in less than 4% of patients.
Postmarketing experience: The following reactions have been identified during postmarketing use of LATISSE® in clinical practice: burning sensation (eyelid), erythema periorbital, eye swelling, eyelid irritation, eyelid edema, eyelid pruritus, iris hyperpigmentation, lacrimation increased, madarosis and trichorrhexis (temporary loss of a few eyelashes to loss of sections of eyelashes, and temporary eyelash breakage, respectively), rash (including macular, erythematous, and pruritic limited to the eyelids and periorbital region), skin discoloration (periorbital), and vision blurred.